Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | CDC25C | P30307 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556819 | 0.92 | CDC25A (0.51) | POLBCDC25ACDC25BCDC25CNPSR1 | |
| SCHEMBL2399162 | 0.85 | CDC25A (0.45) | CDC25ACDC25BCDC25CTP53TSHR | |
| SCHEMBL2399863 | 0.84 | CDC25A (0.42) | POLBCDC25ACDC25BCDC25CTSHR | |
| SCHEMBL2404197 | 0.84 | CDC25A (0.44) | CDC25ACDC25BCDC25CNPSR1TP53 | |
| SCHEMBL2401270 | 0.82 | HPGD (0.48) | CDC25ACDC25BCDC25CTSHRMAPT | |
| SCHEMBL2399858 | 0.80 | ALDH1A1 (0.40) | POLBCDC25ACDC25BCDC25CNPSR1 | |
| SCHEMBL2403283 | 0.79 | CDC25A (0.52) | POLBCDC25ACDC25BCDC25CTSHR | |
| SCHEMBL2398551 | 0.79 | CDC25A (0.38) | POLBCDC25ACDC25BCDC25CNPSR1 | |
| SCHEMBL2398451 | 0.79 | CDK4 (0.48) | CDC25ACDC25BCDC25CTSHRALDH1A1 | |
| SCHEMBL3548778 | 0.76 | CDC25A (0.60) | CDC25ACDC25BCDC25CTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | claimed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | claimed |
| US-8017637-B2 | Inhibitors of cdc phosphatases | IPSEN PHARMA S.A.S. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | disclosed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | disclosed |
| EP-1831209-A2 | CDC25 PHOSPHATASE INHIBITORS | Société de Conseils de Recherches et d'Applications Scientifiques SAS (S.C.R.A.S) (FR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067311-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | CDC25C, CDC25A, CDC25B | POLB 2148/4885CDC25A 2/4885CDC25B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.